SCHEMBL20119480

SCHEMBL20119480

Nc1nn2ccc(N3CCCC3c3cc(F)ccc3F)nc2c1Br

nearest known ligand 0.62

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 20/20 0.62
▸ JAK2 O60674 7/20 0.61
▸ NTRK3 Q16288 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119390 1.00 NTRK1 (0.62) NTRK1JAK2NTRK3
SCHEMBL20119343 0.89 NTRK1 (0.61) NTRK1JAK2NTRK3
SCHEMBL28938482 0.86 NTRK1 (0.63) NTRK1JAK2NTRK3
SCHEMBL28938478 0.86 NTRK1 (0.63) NTRK1JAK2NTRK3
SCHEMBL23865313 0.86 NTRK1 (0.58) NTRK1JAK2NTRK3
SCHEMBL21319641 0.86 NTRK1 (0.58) NTRK1JAK2NTRK3
SCHEMBL21319490 0.86 NTRK1 (0.60) NTRK1JAK2NTRK3
SCHEMBL23865306 0.86 NTRK1 (0.58) NTRK1JAK2NTRK3
SCHEMBL23865301 0.86 NTRK1 (0.58) NTRK1JAK2NTRK3
SCHEMBL21313050 0.85 NTRK1 (0.64) NTRK1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3533796-B1 AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2021-09-29 — — EP disclosed
EP-3533796-B1 AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2021-09-29 — — EP disclosed
US-10829492-B2 Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2020-11-10 — — US disclosed
US-10829492-B2 Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2020-11-10 — — US disclosed
US-20190352306-A1 AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) 2019-11-21 — — US disclosed
US-20190352306-A1 AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) 2019-11-21 — — US disclosed
EP-3533796-A1 AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2019-09-04 — — EP disclosed
EP-3533796-A1 AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2019-09-04 — — EP disclosed
WO-2018077246-A1 AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR 正大天晴药业集团股份有限公司 2018-05-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10829492-B2 Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor NTRK2, BDNF, NTRK1 NTRK1 3/4885JAK2 291/4885NTRK3 5/4885
US-20190352306-A1 AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR NTRK2, BDNF, NTRK1 NTRK1 3/4885JAK2 291/4885NTRK3 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback